Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Dyax And ViroPharma: An Overview Of HAE SpaceLifeSci Advisors • Tue, Sep 18, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
3 Outperforming Micro Caps Under $5 On Winning StreaksKapitall • Tue, Jun 5, 2012
-
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As BuyZetaKap • Fri, May 25, 2012
-
-
-
-
-
-
-
-
Biotech Deal Activity Takes a BreatherThe Burrill Report • Sun, Apr 4, 2010 -
-
Dyax Corp. Q2 2010 Earnings Call TranscriptWed, Jul 28, 2010
-
Dyax Corporation Q1 2010 Earnings Call TranscriptSat, May 1, 2010
-
Dyax Q4 2009 Earnings Call TranscriptWed, Feb 17, 2010
-
Dyax Corp. Q3 2009 Earnings Call TranscriptWed, Oct 28, 2009
-
Dyax Corp. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
Dyax Q1 2009 Earnings Call TranscriptWed, Apr 22, 2009
-
Dyax Corp. Q4 2008 Earnings Call TranscriptWed, Feb 25, 2009
-
Dyax Corporation Q3 2008 Earnings Call TranscriptTue, Nov 4, 2008
-
Dyax Corp. Q2 2008 Earnings Call TranscriptWed, Jul 23, 2008
-
Business Wire (May 23, 2013)
-
Business Wire (May 13, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 18, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Mar 8, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 20, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Feb 5, 2013)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Oct 24, 2012)
-
Business Wire (Oct 17, 2012)
-
Business Wire (Oct 16, 2012)
DYAX vs. ETF Alternatives
Company Description
We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. We use our proprietary drug discovery technology, known as phage display, to... More
